Both transtuzumab and pertuzumab are included in this product for their capacity to actively target domains IV and II of the epidermal growth factor receptors (EGFR) respectively, that are overexpressed in several cancers like breast, cervical and intestinal cancers [117,118]. This evidence concerns the gene EGFR and intestinal cancer.